Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine

[Business Wire] – Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by . . . → Read More: Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine Similar Articles: Pfizer Inc (NYSE:PFE) – Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders Market Update (NYSE:PFE): Pfizer Launches 2013 Integrated Annual Review